Case Studies

Learn how Syngene’s PD-1 neutralizing antibody bioassay reduced donor variability and drug interference for immunogenicity assessment. Read the full case study today.

Syngene’s MSD-based ADA assay enabled sensitive, drug-tolerant immunogenicity assessment for a clinical siRNA therapeutic in regulated studies. Learn more.

See how Syngene used MSD platform pharmacokinetics and immunogenicity assays to de-risk a half-life extended bispecific antibody in oncology. Explore the case study.

Discover how Syngene developed a fit-for-purpose PK assay for a novel bispecific nanobody, achieving a 1.00 to 1000 ng/mL dynamic range and a low 1% repeat rate to support clinical dose selection.

Syngene enhances ADME studies with automated liver microsomal stability assays, improving DMPK precision, boosting throughput, and accelerating ADME screening workflows.

In this case study, you would learn how Syngene enabled a hybrid, device-based IPF cough trial in India for a clinical-stage pharma company—delivering seamless formulation-to-site execution with robust data integrity, regulatory navigation, and on-time delivery.

Renewable energy sources are powerful energy alternatives that can tackle climate change challenges and fossil fuel depletion. The Performance & Specialty Materials (PSM) team at Syngene aimed to develop innovative materials for a customer advancing in clean energy solutions such as green hydrogen. This project contributes to global decarbonization efforts by addressing the challenges in developing the required functional material.

The current immediate-release (IR) tablet formulation for epilepsy1 , available in Europe, requires multiple doses due to the drug’s short half-life, making it inconvenient for patients. This case study explores the development of an extended-release (ER) formulation by Syngene’s Formulation Development team for an anti-epileptic drug, aimed at reducing the need for frequent dosing and helping patients suffering from epilepsy.

The GEM-DIMER™ platform is a proprietary technology developed by Hinge Bio. This technology allows the production of antibodies with enhanced multivalency and multispecificity, enabling the simultaneous targeting of multiple diseaseassociated antigens

The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top ten global public health threats. Despite concerted global efforts, AMR infections caused 4.95 Mn deaths in 2019. A clinical-stage biopharmaceutical company has been working on AMR since 2016 in collaboration with Syngene.